This session highlights several top lung cancer abstracts at STS2021, focusing on lung cancer staging and factors that influence oncologic outcomes.

*Unless otherwise noted, speakers have nothing to disclose.

Moderators

Brendon Stiles (Commercial Relationships: AstraZeneca: Consultant/Advisory Board; Bristol Myers Squibb, Consultant/Advisory Board; Flame Biosciences, Consultant/Advisory Board; Genentech, Consultant/Advisory Board; Lung Cancer Research Foundation, Non-remunerative positions of influence; Pfizer USA, Consultant Advisory/Board, Ownership interest-wife stock former employee; PPD, Ownership interest-wife stock former employee)

Digital Moderators

Virginia Litle

Presentations:

1. Routine Systematic Sampling vs. Selective Targeted Sampling of Lymph Nodes During Endobronchial Ultrasound: A Feasibility Randomized Controlled Trial - Kerrie Sullivan

2. Sampling of N1 and N2 stations should be mandatory during resection of subcentimeter T1aN0M0 NSCLC tumor - Aaron Dezube

3. Textbook Oncologic Outcomes for Lung Cancer Surgery in the United States: How Often Do We Get It Right? - Ann Hwalek

4. Panel Discussion

5. Influence of Hospital Procedure Volume on Mortality and Length of Stay Following Lung Cancer Resection in a Single Payer Healthcare System - Stephan Soder

6. The Impact of Expedited Discharge on 30-Day Readmission Following Lung Resection: An analysis utilizing the Nationwide Readmissions Database - Zachary Tran

7. Panel Discussion